Latest From NextCure Inc.
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.
Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.
Q1 biopharma financing totaled $5.7 billion, a sharp drop from Q4, but this time early-stage venture rounds were the most popular fundraising vehicle;Q1 M&A also declined, totaling $12.3 billion, mostly from Mylan's $9.9 billion buy of Meda. The top alliance was again by Sanofi, in a five-year potential $2.26 billion collaboration with DiCE Molecules to develop oral small-molecule therapies against up to 12 targets.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research, Analytical Equipment and Supplies sectors. This month’s column covers deals announced December 2015 through January 2016.
- Large Molecule
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- NextCure Inc.
- Senior Management
Michael Richman, Pres. & CEO
Steven P Cobourn, CFO
Solomon Langermann, PhD, SVP, Research
Kevin H Heller, MD, CMO
Timothy Mayer, PhD, VP, Bus. Dev.
- Contact Info
Phone: (240) 399-4900
9000 Virginia Manor Rd.
Beltsville, MD 20705
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.